The capital market was last updated on April 30, 2021 at 09:16 IST
Dr. Reddy's Laboratories and its subsidiaries announced the launch of Albenza Tablets, USP, which is the therapeutic equivalent of Albenza Tablets and has been approved by the US Food and Drug Administration (USFDA).
According to data from IQVIA Health, in the most recent twelve months ending in November 2020, sales of the Albenza brand and generic drugs in the United States were approximately US$27 million.
Dr. Reddy’s albendazole tablets, USP has 200 mg tablets, the number of bottles is two bottles. Albenza is a trademark of GlaxoSmithKline.
Albendazole is an anthelmintic used to treat parenchymal neurocysticercosis caused by active lesions caused by the larval form of the swine tapeworm. It is also used to treat cystic echinococcosis of the liver, lungs and peritoneum caused by the larvae of the dog tapeworm Echinococcus granulosus.
The announcement was announced yesterday, after the trading hours on April 29, 2021. The stock price of Dr. Reddy's laboratory rose by 1.15% yesterday to close at 5,101.35 rupees.
Dr. Reddy's Laboratories is a comprehensive pharmaceutical company. Through its three businesses-pharmaceutical services and active ingredients, global generic drugs and proprietary products-Dr. Reddy provides a range of products and services, including APIs, customized pharmaceutical services, generic drugs, biosimilars and differentiated formulations.
Supported by the capital market-real-time news
(This story has not been edited by Business Standard staff and was automatically generated from the joint feed.)
Business Standard has always been committed to providing up-to-date information and comments on developments that interest you, and to have a broader political and economic impact on the country and the world. Your encouragement and constant feedback on how to improve our products will only make us more firmly committed to these ideals. Even in these difficult times caused by Covid-19, we will continue to work to keep you informed and updated with reliable news, authoritative opinions and insightful comments on relevant hot issues. However, we have a requirement. As we fight the economic impact of the pandemic, we need your support even more so that we can continue to provide you with more quality content. Our subscription model has received positive responses from many people who subscribe to our online content. More subscriptions to our online content will only help us achieve our goal of providing you with better and more relevant content. We believe in free, fair and credible news. The support you get through more subscriptions can help us live the journalism we promised. Support high-quality news and subscribe to commercial standards. Digital editor
Copyright © 2021 Business Standards Pte Ltd. all rights reserved.
Business Standard is pleased to inform you of the launch of "Business Standard Advanced Service"
As a premium subscriber, you have unlimited access to a range of services across devices, including:
Welcome to use the quality service of Business Standard provided by FIS. Please visit the Manage My Subscription page to learn about the benefits of this program. Enjoy reading! Team Business Standard